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Abstract
Background: In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7) or 13-
valent (PCV-13) pneumococcal conjugate vaccine at 2, 4 and 12 months of age. At 13 months of age, most of these children
had pneumococcal serotype-specific IgG concentrations $0.35 mg/ml and opsonophagocytic assay (OPA) titers $8.
Methods: Children who had participated in the original study were enrolled again at 3.5 years of age. Persistence of
immunity following infant immunization with either PCV-7 or PCV-13 and the immune response to a PCV-13 booster at pre-
school age were investigated.
Results: In total, 108 children were followed-up to the age of 3.5 years and received a PCV-13 booster at this age. At least
76% of children who received PCV-7 or PCV-13 in infancy retained serotype-specific IgG concentrations$0.35 mg/ml against
each of 5/7 shared serotypes. For serotypes 4 and 18C, persistence was lower at 22–42%. At least 71% of PCV-13 group
participants had IgG concentrations$0.35 mg/ml against each of 4/6 of the additional PCV-13 serotypes; for serotypes 1 and
3 this proportion was 45% and 52%. In the PCV-7 group these percentages were significantly lower for serotypes 1, 5 and
7F. A pre-school PCV-13 booster was highly immunogenic and resulted in low rates of local and systemic adverse effects.
Conclusion: Despite some decline in antibody from 13 months of age, these data suggest that a majority of pre-school
children maintain protective serotype-specific antibody concentrations following conjugate vaccination at 2, 4 and 12
months of age.
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Introduction
The encapsulated bacterium Streptococcus pneumoniae (pneumo-
coccus) is responsible for a considerable burden of disease in young
children, both invasive disease such as meningitis, as well as
mucosal infection such as otitis media and pneumonia. Worldwide
more than 14 million episodes of serious pneumococcal disease
and about 800,000 deaths in children under the age of five years
occur annually [1–3].
Healthy pre-school children frequently carry pneumococci in
the nasopharynx [4,5]. Young children have the highest rates of
pneumococcal colonization and are therefore thought to be the
main transmitters of pneumococci throughout the population
including to other young children and the elderly [6], which may
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e91413
result in disease in these populations. Maintaining adequate
(functional) antibody levels in pre-school children is the key to
sustained direct protection of these vaccinated individuals, as well
as blocking transmission of the organism to achieve herd
protection. Both are presumed to be mediated by antibody.
Pneumococcal conjugate vaccines (PCVs) are highly effective in
preventing carriage of the serotypes contained in the vaccine and
thus disease [7]. Previous immunogenicity studies showed that
with the currently used infant immunization schedules, immunity
to pneumococcal serotypes wanes rapidly during the 2nd year of
life [8,9].
In a previously reported phase II parallel-group, randomized,
active-controlled, double-blind, multicenter trial [10], 278 children
received either PCV-7 or PCV-13 at 2, 4 and 12 months of age
along with routine immunizations for the United Kingdom. In this
follow-on study, we evaluated the persistence of serotype-specific
antibody at 3.5 years of age in individuals who had been enrolled
into the earlier trial. In addition, we investigated the immunoge-
nicity and reactogenicity of a PCV-13 vaccine booster at this age,
comparing individuals previously primed with PCV-7 or PCV-13.
The PCV-13 booster was studied at an age at which UK children
routinely receive their pre-school immunizations as a possibility to
enhance and maintain antibody levels in children under the age of
five and to assess immunological questions relating to how PCV-7
vaccinated individuals respond to the 6 additional serotypes only
contained in PCV-13.
Methods
Participants, Recruitment and Design
This follow-on, multi-center, open label, phase IV clinical trial
was conducted from May to December 2010 in four sites (Oxford,
London, Bristol, Southampton) across the United Kingdom. Five
sites, enrolling 66 participants in the original study, did not take
part in this follow-on study. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1. Ethical approval
was obtained from the Oxfordshire Research Ethics Committee C
(Reference Number 10/H0606/09) and the study was registered
on Clinicaltrials.gov (registration number: NCT01095471). Po-
tential study participants were those who had completed the initial
infant trial (6096A1; Clinicaltrials.gov registration number:
NCT00384059), were healthy and 39–46 months of age.
Exclusion criteria were similar to the initial study [10] and
included previous anaphylactic reactions to any vaccine or
vaccine-related component, bleeding diathesis, culture proven
sepsis with S. pneumoniae, any serious or chronic ill health (including
immunodeficiency), receipt of blood products, participation in
another investigational study, and the receipt of further doses of
pneumococcal vaccines since the initial study. Written informed
consent was taken by appropriately trained medical or nursing
members of the research team. The parent/guardian and the
person who presented and obtained consent had to personally date
and sign the latest approved version of the consent form before any
study-specific procedures were performed, which was then
retained at the study site. This procedure of taking and
documenting consent was approved by the Oxfordshire Research
Ethics Committee (Reference Number 10/H0606/9).
At visit 1, participants had a blood sample taken, followed by
receipt of a dose of Prevenar 13 (PCV-13; Pfizer Inc., Pearl River,
USA). A second blood sample was drawn at visit 2 (28 to 42 days
after visit 1), together with doses of the routine pre-school
immunizations (second dose of MMR vaccine and DTaP/IPV
pre-school booster), if not already received. Laboratory staff
remained blinded to original trial vaccine group allocation.
Study Objectives
The primary objective of this study was to determine the
proportion of participants immunized with PCV-13 at 2, 4 and 12
months of age, who had serotype-specific immunoglobulin G (IgG)
concentrations $0.35 mg/ml for PCV-13 serotypes at pre-school
age. The secondary objectives were to determine the proportion of
participants with pre-booster serotype-specific IgG $0.35 mg/ml
for PCV-13 serotypes in the PCV-7 group; the proportion of
participants with opsonophagocytic assay (OPA) titers $8 for
PCV-13 serotypes in both groups; and the immunogenicity as well
as the reactogenicity of a booster dose of PCV-13 given at
approximately 3.5 years of age.
Vaccines and Interventions
PCV-13 is formulated in a similar manner to PCV-7 containing
serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and includes the additional
serotypes 1, 3, 5, 6A, 7F, and 19A [11]. PCV-13 was administered
to all participants intramuscularly into the deltoid muscle during
visit 1, which took place at the participants’ homes by trained
members of the research team. Routine pre-school booster
immunizations were also administered to those who required
them following the UK immunization program at visit 2. All
vaccines were presented in prefilled syringes.
Laboratory Measurements
Serum was separated within 24 hours of sampling and stored at
280uC. In both groups, PCV-13 serotype-specific IgG antibody
concentrations were tested at Pfizer Vaccine Research, Pearl
River, USA as previously described [10]. OPA titers against PCV-
13 serotypes were calculated as the interpolated reciprocal dilution
of test serum that causes a 50% reduction of bacteria surviving the
opsonophagocytic reaction incubation. A titer of 4 was allocated to
sera with undetectable OPAs, the titer of 8 being the lowest
positive result. Serotype-specific antibody concentrations of $
0.35 mg/ml and OPA titers $8 were used as putative correlates of
immunity against serotype-specific IPD [1,12].
Statistical Analysis
Data were log10-transformed prior to analysis and results of
group comparisons on log scales were presented as geometric
means in each group, with 95% confidence interval and associated
p-value from independent samples t-tests for the group compar-
ison. Binary variables were presented as counts and proportions or
percentages within each group, with 95% CI calculated using the
binomial exact method and comparisons performed using chi-
square tests. All statistical tests were 2-sided and p-values less than
0.05 were considered significant. For each participant the number
of serotypes above threshold was calculated and standardized to 13
serotypes (to account for a small number of participants with some
missing serotypes) by dividing the number of serotypes above
threshold by the number of serotypes with available data for that
participant. Participants were analyzed according to the group to
which they had been randomized in the initial study. Statistical
analysis were performed using SAS version 9.2 (SAS Institute Inc.,
Cary, NC, USA) and R [13].
Results
Out of 278 participants enrolled in the original study, 191 were
eligible for the follow-on study. Of these, 108 children were
enrolled into the follow-on study and received the booster vaccine.
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The parents of one child withdrew consent before visit 2 and 1
child was lost to follow-up, resulting in 106 participants who
completed visit 2 (Figure 1). The age, gender, time since last
pneumococcal conjugate vaccination and the time interval
between visit 1 and visit 2 were similar in both groups (Table 1).
Figure 1. Flow chart of participants through the study.
doi:10.1371/journal.pone.0091413.g001
Table 1. Summary of study participants’ characteristics.
PCV-13 (N= 56) PCV-7 (N= 52)
Proportion of female study participants 28 (50%) 28 (54%)
Proportion of White Caucasian study participants 54 (96%) 48 (92%)
Mean age at Visit 1 in years (range) 3.50 (3.16–4.09) 3.51 (3.15–4.04)
Mean time since 12-month booster to Visit 1 in years (range) 2.49 (2.13–3.07) 2.51 (2.15–2.97)
Mean time interval between Visit 1 - Visit 2 in days (range) 34.9 (26.5–56.5) 35.0 (27.6–42.6)
doi:10.1371/journal.pone.0091413.t001
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Antibody Persistence to Pre-school Years
Approximately 2.5 years after completion of a 2+1 immuniza-
tion schedule with PCV-13, most children had serotype-specific
IgG concentrations $0.35 mg/ml, for the majority of serotypes
against which they had been immunized (median number of
serotypes with IgG above threshold: 10). This was also true for
children immunized with PCV-7 as the primary vaccine (median
number of serotypes with IgG above threshold: 9; Figure 2). Before
the pre-school booster $76% of participants had IgG concentra-
tions $0.35 mg/ml for 5 of the 7 shared serotypes, the exceptions
being serotypes 4 and 18C (Table 2 and Figure 3). A significantly
higher proportion of participants had IgG concentrations $
0.35 mg/ml for serotype 4 in PCV-7 recipients compared with
participants in the PCV-13 group (Figure 3). For the 6 additional
PCV-13 serotypes, IgG concentrations $0.35 mg/ml were present
in almost all participants in both groups for serotypes 6A and 19A
(and 83 and 96% for serotype 5 in the PCV-7 and PCV-13 groups,
respectively). Between the groups the proportions of participants
with IgG concentrations $0.35 mg/ml were significantly higher in
PCV-13 than PCV-7 recipients for serotypes 1, 5 and 7F (Table 2
and Figure 3).
Serotype specific IgG geometric mean concentrations (GMCs)
were significantly higher in PCV-13 than PCV-7 recipients for
serotypes 1, 7F and 19A (Figure 4 and Table 3), but did not
significantly differ for the other three serotypes contained only in
PCV-13. For serotypes included in both vaccines, only serotype 4
was significantly different between the groups (slightly higher in
the PCV-7 group).
Serotype-specific functional antibodies were also assessed by
OPA. Similar to the IgG data, a high proportion of participants
had OPA titers $8 for most of the serotypes in the PCV-13 group
(median number of serotypes with OPA above threshold: 9), which
was significantly lower for the PCV-7 group with a median of 7.1
(Figure 2, p,0.001). Before the PCV-13 booster, proportions of
participants with OPA titers $8 for the 7 shared serotypes were
high for serotypes 9V and 14 (82–86%), 63–83% for 6B, 19F and
23F and lower for serotypes 18C (52–57%) and 4 (29–30%)
(Figure 3). For the 6 additional serotypes OPA titers $8 were
observed in 85–94% of PCV-13 group participants for serotypes 3,
7F and 19A and 74% for 6A, but were lower for serotypes 1 (27%)
and 5 (35%) (Figure 3). In the PCV-7 group, 69–74% of
participants had OPA titers $8 for serotypes 7F and 19A, 45–
49% for 3 and 6A and very few participants had detectable OPA
titers against serotypes 1 and 5 (Table 4). OPA geometric mean
titers (GMTs) at 40 months of age before the PCV-13 booster were
similar between the groups for the shared serotypes. As for the
PCV-13 serotypes, significant differences were observed for
serotypes 1, 3, 5, 6A and 19A but not for serotype 7F, for which
there were very high OPA titers in both groups (Table 5 and
Figure 4).
Immunogenicity of the PCV-13 Pre-school Booster
IgG GMCs and OPA GMTs following the booster dose are
shown in Table 3 and 5; these values were significantly higher than
pre-booster for all serotypes (all p-values ,0.00001, data not
shown). All participants from both groups had IgG concentrations
$0.35 mg/ml for all serotypes with the exception of serotype 3
(PCV-13 group: 96% and PCV-7 group: 89%; Figure 3). Post-
booster antibody GMCs were significantly higher in the PCV-13
group for 5/6 of the additional serotypes only included in PCV-13,
except for serotype 3 (Table 3 and Figure 4). Following the PCV-
13 booster, all participants had OPA titers $8 for all serotypes.
Significant differences in post-booster GMTs were observed for
serotypes 6B and 23F from the shared serotypes (higher in the
PCV-7 group) and for serotypes 1 (higher in the PCV-13 group)
and 7F (higher in the PCV-7 group) – Table 5 and Figure 4.
Reactogenicity
No serious adverse events were recorded following the PCV-13
booster at 3.5 years of age. Local reactions such as redness,
hardness and swelling were either absent or mild in most cases.
However, moderate or severe tenderness was experienced by 18%
Figure 2. Standardized number of serotypes above thresholds. Box plots of standardized number of serotypes above thresholds (IgG $
0.35 mg/ml and OPA titers$8) at 3.5 years in each of the groups [standardized to 13 serotypes]. The median is shown as a line across the box with the
box representing the lower and upper quartiles. Whiskers extend to the maximum or minimum values within 1.5 times the IQR above and below the
3rd and 1st quartile, respectively. Points outside this range are represented as dots.
doi:10.1371/journal.pone.0091413.g002
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Figure 3. Proportion of participants with serotype-specific IgG concentrations and OPA titers above thresholds. Proportion of
participants with serotype-specific IgG concentrations and OPA titers above a threshold of 0.35 mg/ml and 8, respectively, for each of the serotypes
before (40 months, 40 mo) and after (41 months, 41 mo) the PCV-13 booster. Shown are mean values along with their 95% confidence intervals. Red
lines are shown at the bottom if p-values from chi-square test of proportions between the groups were significant (p-values #0.05, #0.01, #0.001,
and #0.0001 are represented by 1, 2, 3, and 4 lines).
doi:10.1371/journal.pone.0091413.g003
Table 2. Proportion of participants with serotype-specific IgG concentrations $0.35 mg/ml.
––––– PREBOOSTER –40 months ––––– –– POSTBOOSTER –41 months ––
Proportion $0.35 mg/ml (95% CI)* P value** Proportion $0.35 mg/ml (95% CI)*
Serotype PCV-13 PCV-7 PCV-13 PCV-7
4 0.22 (0.12, 0.36) 0.42 (0.29, 0.57) 0.0284 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
6B 0.98 (0.90, 1.00) 0.98 (0.90, 1.00) 0.9889 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
9V 0.78 (0.65, 0.89) 0.83 (0.70, 0.92) 0.5847 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
14 0.76 (0.63, 0.87) 0.78 (0.65, 0.89) 0.8127 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
18C 0.31 (0.19, 0.46) 0.38 (0.25, 0.53) 0.4506 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
19F 0.92 (0.81, 0.98) 0.94 (0.84, 0.99) 0.6759 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
23F 0.84 (0.71, 0.93) 0.92 (0.81, 0.98) 0.2061 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
6A{ 1.00 (0.93, 1.00) 0.96 (0.87, 1.00) 0.1573 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
1{ 0.45 (0.31, 0.60) 0.14 (0.06, 0.27) 0.0006 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
3{ 0.52 (0.37, 0.66) 0.59 (0.43, 0.73) 0.5099 0.96 (0.87, 1.00) 0.89 (0.76, 0.96)
5{ 0.96 (0.87, 1.00) 0.83 (0.70, 0.92) 0.0279 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
7F{ 0.71 (0.56, 0.83) 0.39 (0.25, 0.54) 0.0014 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
19A{ 1.00 (0.93, 1.00) 0.98 (0.90, 1.00) 0.3196 1.00 (0.93, 1.00) 1.00 (0.92, 1.00)
*Binomial exact confidence interval;
**P Value from chi-square test of proportions at 40 months, no comparisons were made at 41 months as almost all proportions were 1;
{Serotypes only present in PCV-13.
doi:10.1371/journal.pone.0091413.t002
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Table 3. Serotype-specific geometric mean concentrations before and after the booster at 40 and 41 months of age with t-tests.
––––– PREBOOSTER –40 months ––––– ––––– POSTBOOSTER –41 months –––––
GMC (95% CI) P value** GMC (95% CI) P value**
Serotype PCV-13 PCV-7 PCV-13 PCV-7
4 0.20 (0.16, 0.24) 0.28 (0.22, 0.36) 0.0267 7.37 (5.80, 9.37) 8.72 (6.48, 11.73) 0.3744
6B 2.79 (2.06, 3.78) 3.28 (2.35, 4.57) 0.4779 37.82 (29.57, 48.37) 40.25 (28.78, 56.28) 0.7616
9V 0.76 (0.59, 0.98) 0.91 (0.69, 1.19) 0.3532 6.43 (5.06, 8.16) 6.23 (4.89, 7.94) 0.8546
14 0.75 (0.54, 1.02) 0.91 (0.65, 1.28) 0.3800 22.51 (17.00, 29.82) 21.51 (16.41, 28.18) 0.8145
18C 0.22 (0.16, 0.30) 0.31 (0.23, 0.41) 0.1051 4.33 (3.48, 5.41) 4.25 (3.25, 5.55) 0.9054
19F 2.30 (1.55, 3.42) 2.65 (1.78, 3.94) 0.6135 22.18 (17.05, 28.87) 15.29 (11.16, 20.96) 0.0701
23F 1.48 (1.05, 2.10) 1.31 (0.99, 1.72) 0.5646 9.10 (7.33, 11.32) 10.25 (7.84, 13.39) 0.4897
6A{ 3.04 (2.34, 3.94) 2.14 (1.63, 2.83) 0.0684 26.81 (21.01, 34.20) 13.55 (9.27, 19.80) 0.0032
1{ 0.45 (0.32, 0.62) 0.10 (0.07, 0.15) ,.0001 10.16 (8.04, 12.84) 2.03 (1.61, 2.56) ,.0001
3{ 0.71 (0.40, 1.28) 0.56 (0.32, 0.99) 0.5552 2.18 (1.59, 2.98) 1.71 (1.16, 2.52) 0.3357
5{ 1.22 (0.97, 1.53) 1.11 (0.84, 1.48) 0.6168 10.46 (8.34, 13.13) 2.28 (1.84, 2.81) ,.0001
7F{ 0.67 (0.51, 0.90) 0.25 (0.17, 0.37) ,.0001 7.82 (6.38, 9.59) 4.32 (3.33, 5.61) 0.0004
19A{ 5.34 (3.84, 7.42) 2.75 (2.11, 3.58) 0.0020 15.70 (12.62, 19.54) 9.49 (7.54, 11.94) 0.0019
**P value from independent samples t-test using Satterthwaites method for unequal variances where appropriate.
{Serotypes only present in PCV-13 vaccine.
doi:10.1371/journal.pone.0091413.t003
Figure 4. Serotype-specific IgG GMCs and OPA GMTs. Box plots of IgG GMCs and OPA GMTs for each of the serotypes before (40 months,
40 mo) and after (41 months, 41 mo) the PCV-13 booster. The median is shown as a line across the box with the box extending to the lower and
upper quartiles, respectively. The whiskers extend to the maximum or minimum values within 1.5 times the IQR above and below the 3rd and 1st
quartile, respectively. Points outside this range are represented as dots. Means are shown as a diamonds and t-test were performed for each serotype
at each time point between the groups with p-values being represented as red lines if significant (1, 2, 3, and 4 lines if p#0.05,#0.01,#0.001, and#
0.0001, respectively).
doi:10.1371/journal.pone.0091413.g004
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of all participants (Table 6). Decreased appetite and irritability
were recorded in 18% and 41% of participants, respectively,
which were moderate or severe in 4% and 13% of children. Low-
grade fever (38–39uC) was noted in 3% of the participants and
none of the children had a temperature .39uC (Table 6). The
reactogenicity profile of the PCV-13 booster was similar regardless
of whether participants had previously been immunized with
PCV-7 or PCV-13.
Discussion
This is to our knowledge the first clinical trial investigating the
persistence of total and opsonophagocytic serotype-specific anti-
bodies up to the age of 3.5 years following a CRM197-based 7- or
13-valent PCV schedule. We have shown that sustained effective-
ness of both direct and indirect effects can be anticipated on a
population level if based on the currently accepted ‘‘protective
thresholds’’. For the PCV-7 serotypes, this finding is consistent
Table 4. Proportion of participants with serotype-specific OPA titers $8.
––––– PREBOOSTER –40 months ––––– –– POSTBOOSTER –41 months ––
Proportion OPA $8 (95% CI)* P value** Proportion OPA $8 (95% CI)*
Serotype PCV-13 PCV-7 PCV-13 PCV-7
4 0.30 (0.16, 0.47) 0.29 (0.16, 0.44) 0.9336 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
6B 0.78 (0.62, 0.89) 0.71 (0.56, 0.84) 0.5021 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
9V 0.86 (0.73, 0.95) 0.84 (0.71, 0.94) 0.7977 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
14 0.82 (0.67, 0.92) 0.83 (0.70, 0.93) 0.8481 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
18C 0.52 (0.37, 0.68) 0.57 (0.42, 0.72) 0.6201 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
19F 0.63 (0.47, 0.77) 0.72 (0.57, 0.84) 0.3681 1.00 (0.91, 1.00) 1.00 (0.91, 1.00)
23F 0.72 (0.56, 0.85) 0.83 (0.69, 0.92) 0.2350 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
6A{ 0.74 (0.58, 0.86) 0.49 (0.33, 0.65) 0.0192 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
1{ 0.27 (0.15, 0.42) 0.04 (0.00, 0.13) 0.0013 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
3{ 0.85 (0.72, 0.94) 0.45 (0.31, 0.60) ,.0001 1.00 (0.93, 1.00) 1.00 (0.91, 1.00)
5{ 0.35 (0.21, 0.50) 0.0 (0.0, 0.08) ,.0001 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
7F{ 0.91 (0.78, 0.97) 0.76 (0.60, 0.89) 0.0712 1.00 (0.92, 1.00) 1.00 (0.91, 1.00)
19A{ 0.94 (0.83, 0.99) 0.69 (0.53, 0.82) 0.0019 1.00 (0.93, 1.00) 1.00 (0.91, 1.00)
*Binomial exact confidence interval;
**P Value from chi-square test of proportions at 40 months, no comparisons were made at 41 months as all proportions were 1;
{Serotypes only present in PCV-13.
doi:10.1371/journal.pone.0091413.t004
Table 5. Serotype-specific geometric mean OPA titers before and after the booster at 40 and 41 months of age with t-tests.
––––– PREBOOSTER –40 months ––––– ––––– POSTBOOSTER –41 months –––––
GMT (95% CI) P value** GMT (95% CI) P value**
Serotype PCV-13 PCV-7 PCV-13 PCV-7
4 22.98 (9.13, 57.82) 19.47 (8.99, 42.19) 0.7797 4453 (3407, 5821) 3320 (2373, 4644) 0.1671
6B 338.6 (145.3, 789.3) 241.1 (103.7, 560.5) 0.5690 6605 (5013, 8702) 9962 (7313, 13571) 0.0478
9V 240.5 (126.2, 458.4) 229.7 (118.7, 444.3) 0.9200 5069 (4149, 6193) 4433 (3547, 5540) 0.3675
14 337.3 (171.7, 662.5) 264.3 (147.8, 472.6) 0.5808 3179 (2551, 3961) 2886 (2244, 3711) 0.5593
18C 50.37 (21.32, 119.0) 56.72 (25.52, 126.1) 0.8386 7530 (5780, 9809) 5119 (3713, 7058) 0.0624
19F 59.72 (27.45, 130.0) 73.30 (37.42, 143.6) 0.6877 2249 (1612, 3140) 2496 (1743, 3576) 0.6682
23F 179.4 (76.38, 421.3) 291.7 (142.5, 597.2) 0.3792 2972 (2316, 3815) 4466 (3236, 6162) 0.0452
6A{ 172.4 (78.84, 376.8) 45.43 (19.84, 104.1) 0.0204 7023 (5072, 9724) 8814 (6351, 12232) 0.3251
1{ 8.02 (5.34, 12.04) 4.45 (3.80, 5.21) 0.0086 588.2 (435.8, 793.9) 175.2 (140.6, 218.3) ,.0001
3{ 46.37 (28.61, 75.13) 16.16 (9.86, 26.50) 0.0028 227.1 (183.3, 281.4) 209.9 (171.3, 257.2) 0.5965
5{ 8.00 (5.93, 10.79) 4.00 (4.00, 4.00) ,.0001 1296 (976.5, 1719) 921.6 (683.8, 1242) 0.0978
7F{ 677.2 (380.0, 1207) 354.3 (148.7, 844.5) 0.2134 4696 (3866, 5704) 9313 (7287, 11902) ,.0001
19A{ 187.0 (105.7, 330.8) 50.25 (27.27, 92.60) 0.0021 1557 (1261, 1923) 1649 (1276, 2131) 0.7274
**P value from independent samples t-test using Satterthwaites method for unequal variances where appropriate.
{Serotypes only present in PCV-13 vaccine.
doi:10.1371/journal.pone.0091413.t005
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with IPD effectiveness data demonstrating almost complete
disappearance of vaccine serotypes over a period of approximately
5–7 years [14–16] so that, at the population level, these responses
appear to be adequate for effective disease control.
Only 2 other studies looked at the persistence of pneumococcal
antibody beyond the second year of life. Silfverdal et al. [17]
assessed the immune response in children aged 36–46 months
previously vaccinated with the 10-valent PCV (PCV-10) in a 2+1
or 3+1 schedule compared to an unvaccinated control group of
children of the same age. Although the focus of their work was to
demonstrate induction of memory by PCV-10, they report
information on the baseline antibody GMC and OPA GMT,
which were generally lower for the majority of the vaccine
serotypes even in the group of children who were vaccinated in a
3+1 schedule compared with our study. In a further study by
Madhi et al. [18] in South Africa, trial participants who had
received 3 doses of PCV-9 at approximately 6, 11 and 16 weeks of
age were followed to approximately 6 years and compared with
unvaccinated controls for age. Efficacy against vaccine-type IPD
remained high (78%) in HIV uninfected children, which was
associated with a high proportion of participants ($75%)
maintaining IgG concentrations $0.35 mg/ml against 5/7 PCV-
7 serotypes. Lower proportions of participants reached the
threshold against serotypes 4 and 18C, which is similar to our
study. No functional antibody measurements by OPA were
performed in that study.
There are data available on persistence of antibody against
other polysaccharide-encapsulated bacteria following immuniza-
tion with glycoconjugate vaccines in infancy [6]. In a recent study,
the proportion of individuals with functional antibodies against
serogroup C meningococci six years after vaccine priming was low
(12–16%) after 2 or 3 doses in infancy [19]. In contrast, persistence
of antibodies after infant vaccination with H. influenzae type b
conjugate was somewhat better with a high proportion of
vaccinees (86–99%) having antibodies above the protective
threshold at age 3–4 years [20,21].
As shown in previous studies there is variation of immunoge-
nicity and persistence between different pneumococcal serotypes.
In the present study, we evaluated the persistence of total and
functional antibody against all PCV-13 serotypes in children who
had received PCV-13 and PCV-7 in a 2+1 schedule. Proportions
of participants with serotype-specific IgG concentrations $
0.35 mg/ml and absolute antibody concentrations were not
different between the groups for the shared serotypes, with the
exception of serotype 4 for which higher responses were found in
the PCV-7 group at 40 months. Data from the original study
showed significant differences between the GMCs from PCV-7
and PCV-13 recipients for serotype 4 at all study visits (5, 12, and
13 months) [10] suggesting that the lower persistence against
serotype 4 in the PCV-13 group observed in this follow-on study is
not a chance finding. The lower antibody levels seen for serotypes
4 and 18C may be acceptable in populations with high PCV
uptake that establishes herd immunity, as shown by large decreases
in invasive disease cases both in vaccinated and unvaccinated
individuals [22]. In the original part of the study, OPA GMTs
were relatively low for serotypes 4, 18C and 19F several months
after vaccination at 12 months of age despite a good initial
immune response [10] indicating that antibodies directed against
these serotypes wane rapidly irrespective of the age at immuni-
zation and the type of vaccine given. The reason for this finding is
unknown and may be partly explained with low carriage rates for
serotype 4 and 18C whereas rates of colonization for serotype 19F
seem to be similar or higher compared with other PCV-7 serotypes
[24,25].
Participants in both groups showed a very good immune
response to all 7 shared serotypes following the pre-school booster
with PCV-13 suggesting that PCV-7 and PCV-13 have compa-
rable priming ability for the shared serotypes. Overall similar
immunogenicity and persistence for these 7 serotypes induced by
the two vaccines is consistent with early PCV-13 post-licensure
data from the UK showing equivalent effectiveness against these
serotypes [23].
Marked differences were present between the groups for the
serotypes contained only in PCV-13 both before and after the pre-
school booster. We found low proportions of participants with
OPA $8 and lower GMTs in the PCV-7 group at baseline and
highly significant differences in GMT between the groups for
serotypes 1 and 5 (Figures 3 and 4). Both serotypes were very
rarely found in carriage studies both before and after introduction
of PCV-7 into the UK routine immunization schedule [7,24,25],
which may account for the low antibody levels seen in the PCV-7
group until the pre-school age compared with the other serotypes
contained only in PCV-13. The significance of lower antibody
persistence for serotypes 1 and 5 is currently unknown although
there is some evidence that herd immunity is rapidly accumulating
for most of the 6 additional serotypes [23], which implies that
transmission at least in part can be blocked. Following the pre-
school booster, significant differences between the groups
remained for serotype 1, but not for serotype 5, when measured
by OPA suggesting that priming with serotype 1 is important
(Table 5). This seems to be less critical for serotype 5 for which
vaccine unprimed individuals mounted a very good immune
response (when measured by OPA) suggesting that at least for this
serotype age may be a more important factor than the number of
previous vaccine doses in determining the amount of functional
antibody generated, as previously shown for other polysaccharide-
containing vaccines [19,21]. Post-licensure surveillance data from
the UK show that children aged ,5 years vaccinated with PCV-7
are not protected against serotypes 1 and 5 [22], which is
consistent with low functional antibody titers in our study in the
PCV-7 group (Figure 4).
Serotypes 6A and 19A are usually referred to as ‘‘cross-reactive’’
serotypes because antibodies induced by serotypes 6B and 19F
cross-react in vitro with those 2 serotypes, respectively. We have
shown in this study that PCV-7 induces high total and functional
antibodies against 6A [10], which also persist at high levels up to
the pre-school years (Figures 3 and 4). There is some evidence
from both the US and the UK that cross-reactive antibodies
against serotype 6A are effective in preventing carriage and disease
[7,16,22,25,26], although serotype 6C isolates were initially
misclassified as 6A, and changes in IPD rates caused by 6A may
also depend on other factors than vaccination [27]. A completely
different picture can be seen for serotype 19A. Although less
pronounced compared with serotype 6A, PCV-7 induces a good
[10] and persistent immune response against serotype 19A in
addition to potential natural acquisition of antibody through
colonization (Figures 3 and 4). Although in vitro these cross-reactive
antibodies appear to be functional, PCV-7 vaccinated children
are, in fact, at increased risk of serotype 19A disease following
widespread PCV-7 immunization, compared with the pre-vaccine
era [16,22], most likely as a result of an increase in 19A carriage
rates [7,25,28]. There are several potential reasons for this
discrepancy between the in vitro and in vivo data: (a) OPA measures
functional antibodies using one particular laboratory strain, which
may differ significantly from disease isolates; (b) higher antibody
concentrations/titers may be necessary to protect against IPD
compared with other serotypes, or antibody-mediated opsono-
phagocytosis may not be the main mechanism of killing for this
Persistence of Pneumococcal Antibody
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serotype; early data from the UK, however, indicate that PCV-13
is highly effective against serotype 19A disease [29]; (c) there is a
theoretical possibility that a small percentage of individuals who
are not able to generate cross-reactive antibodies, along with
increased carriage rates in PCV-7 vaccinated populations, may be
responsible for replacement disease.
In the present study, antibody concentrations and functional
OPA titers against serotypes 3 and 7F in the PCV-7 group
increased over time irrespective of vaccination [10], so that GMC/
GMT were relatively high at 40 months of age (Figure 4).
Although the kinetics of the acquisition of these antibodies suggest
that this increase in (functional) antibody is most likely a result of
natural exposure, low carriage rates were found in young children
both before [26] and after [7,25] routine PCV-7 immunization.
These in vitro functional antibodies don’t appear to be effective in
preventing IPD caused by serotypes 3 and 7F as shown by post-
licensure effectiveness studies [16,22]. It is again unclear how these
antibodies differ from those generated by PCV-13, for which early
vaccine effectiveness against serotype 7F has been demonstrated
[29]. Serotype 3 may behave differently from other serotypes both
in terms of immunogenicity and vaccine efficacy [30,31] and it is
possible that higher thresholds are required to prevent disease
caused by serotype 3 [29].
Limitations and Strengths of the Study
There are several potential limitations to our study. This study
only allows a snapshot of the antibody concentrations and OPA
titers at a certain time point. Differences in serotype epidemiology
due to forces related and unrelated to routine immunization mean
that serology is likely to be different in other populations at
different times. Nevertheless the children studied here, alongside
routine use of PCV-7 in the general population, permit
interpretation of our findings together with UK post-licensure
surveillance data.
Conclusion
We have shown that following PCV-13 immunization at 2, 4
and 12 months of age, antibody persistence against most serotypes
can be expected until the age of at least 3.5 years, which is
consistent with post-licensure IPD effectiveness and carriage data
[14–16]. However, this might not be the case either in situations
with lower vaccine coverage [32] or natural acquired (functional)
antibodies as shown in the present study for serotypes 3, 7F and
19A. Accordingly, serological studies of this kind are important
alongside population surveillance of invasive disease, carriage
studies and information on vaccine coverage to obtain information
on the relationships between vaccine responses and population-
wide effectiveness.
A pre-school booster with PCV-13 is well tolerated with low
rates of local and systemic side effects after priming with either
PCV-7 or PCV-13.
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